Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
AIDS and Behavior
Erschienen in: AIDS and Behavior 6/2018

13.10.2017 | Original Paper

Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection

verfasst von: Theresa Winhusen, Daniel J. Feaster, Rui Duan, Jennifer L. Brown, Eric S. Daar, Raul Mandler, Lisa R. Metsch

Erschienen in: AIDS and Behavior | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Cigarette smoking is prevalent in people living with HIV/AIDS (PLHIV) who abuse alcohol and/or illicit substances. This study evaluated whether smoking is predictive of virologic non-suppression (> 200 copies/mL) and low CD4 count (< 200 cells/mm3) during 1-year follow-up in medically hospitalized, substance-using PLHIV recruited for a multi-site trial. Smoking status was assessed with the Heaviness of Smoking Index (HSI). Analyses revealed that, controlling for baseline differences and adherence to antiretroviral therapy, non-smokers (n = 237), compared to smokers scoring in the medium-to-high range on the HSI (n = 386), were significantly more likely to achieve viral suppression (OR 1.50, 95% CI 1.02, 2.20). There was a significant smoking-by-time interaction for CD4 cell count (χ2(1) = 4.08, p < .05), with smokers less likely to have low CD4 count at baseline and 6-month follow-up, but more likely to have low CD4 count at 12-month follow-up. The results suggest that smoking may play a role in immunological functioning in HIV-infected substance users. ClinicalTrials.gov Identifier: NCT01612169.
Literatur
1.
Duval X, Baron G, Garelik D, et al. Living with HIV, antiretroviral treatment experience and tobacco smoking: results from a multisite cross-sectional study. Antivir Ther. 2008;13(3):389–97.PubMedPubMedCentral
2.
Burkhalter JE, Springer CM, Chhabra R, Ostroff JS, Rapkin BD. Tobacco use and readiness to quit smoking in low-income HIV-infected persons. Nicotine Tob Res. 2005;7(4):511–22.CrossRefPubMed
3.
Pacek LR, Latkin C, Crum RM, Stuart EA, Knowlton AR. Current cigarette smoking among HIV-positive current and former drug users: associations with individual and social characteristics. AIDS Behav. 2014;18(7):1368–77.CrossRefPubMedPubMedCentral
4.
Hile SJ, Feldman MB, Alexy ER, Irvine MK. Recent tobacco smoking is associated with poor HIV medical outcomes among HIV-infected individuals in New York. AIDS Behav. 2016;20(8):1722–9.CrossRefPubMedPubMedCentral
5.
Feldman JG, Minkoff H, Schneider MF, et al. Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women’s interagency HIV study. Am J Public Health. 2006;96(6):1060–5.CrossRefPubMedPubMedCentral
6.
Miguez-Burbano MJ, Burbano X, Ashkin D, Pitchenik A, Allan R, Pineda L, et al. Impact of tobacco use on the development of opportunistic respiratory infections in HIV seropositive patients on antiretroviral therapy. Addict Biol. 2003;8(1):39–43.CrossRefPubMed
7.
Wojna V, Robles L, Skolasky RL, Mayo R, Selnes O, de la Torre T, et al. Associations of cigarette smoking with viral immune and cognitive function in human immunodeficiency virus-seropositive women. ≅. 2007;13(6):561–8.
8.
Gritz ER, Vidrine DJ, Lazev AB, Amick BC 3rd, Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res. 2004;6(1):71–7.CrossRefPubMed
9.
Kabali C, Cheng DM, Brooks DR, Bridden C, Horsburgh CR, Samet JH. Recent cigarette smoking and HIV disease progression: no evidence of an association. AIDS Care. 2011;23(8):947–56.CrossRefPubMedPubMedCentral
10.
Rao P, Ande A, Sinha N, Kumar A, Kumar S. Effects of cigarette smoke condensate on oxidative stress, apoptotic cell death, and HIV replication in human monocytic cells. PLoS ONE. 2016;11(5):e0155791.CrossRefPubMedPubMedCentral
11.
12.
Ande A, McArthur C, Ayuk L, et al. Effect of mild-to-moderate smoking on viral load, cytokines, oxidative stress, and cytochrome P450 enzymes in HIV-infected individuals. PLoS ONE. 2015;10(4):e0122402.CrossRefPubMedPubMedCentral
13.
Ande A, McArthur C, Kumar A, Kumar S. Tobacco smoking effect on HIV-1 pathogenesis: role of cytochrome P450 isozymes. Expert Opin Drug Metab Toxicol. 2013;9(11):1453–64.CrossRefPubMedPubMedCentral
14.
Webb MS, Vanable PA, Carey MP, Blair DC. Cigarette smoking among HIV+ men and women: examining health, substance use, and psychosocial correlates across the smoking spectrum. J Behav Med. 2007;30(5):371–83.CrossRefPubMedPubMedCentral
15.
Shuter J, Bernstein SL. Cigarette smoking is an independent predictor of nonadherence in HIV-infected individuals receiving highly active antiretroviral therapy. ±. 2008;10(4):731–6.PubMed
16.
17.
Roy S, Ninkovic J, Banerjee S, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Nneuroimmune Pharmacol. 2011;6(4):442–65.CrossRef
18.
Wang X, Ma TC, Li JL, et al. Heroin inhibits HIV-restriction miRNAs and enhances HIV infection of macrophages. Front Microbiol. 2015;6:1230.PubMedPubMedCentral
19.
Swepson C, Ranjan A, Balasubramaniam M, Pandhare J, Dash C. Cocaine enhances HIV-1 transcription in macrophages by inducing p38 MAPK phosphorylation. Front Microbiol. 2016;7:823.CrossRefPubMedPubMedCentral
20.
21.
Williams EC, Hahn JA, Saitz R, Bryant K, Lira MC, Samet JH. Alcohol use and human immunodeficiency virus (HIV) infection: current knowledge, implications, and future directions. Alcohol Clin Exp Res. 2016;40(10):2056–72.CrossRefPubMedPubMedCentral
22.
Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retroviruses. 2010;26(5):511–8.CrossRefPubMedPubMedCentral
23.
Humfleet GL, Delucchi K, Kelley K, Hall SM, Dilley J, Harrison G. Characteristics of HIV-positive cigarette smokers: a sample of smokers facing multiple challenges. AIDS Educ Prev. 2009;21(3 Suppl):54–64.CrossRefPubMedPubMedCentral
24.
Metsch LR, Feaster DJ, Gooden L, et al. Effect of patient navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance use: a randomized clinical trial. JAMA. 2016;316(2):156–70.CrossRefPubMedPubMedCentral
25.
Bush K, Kivlahan DR, Donell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol use disorders identification test. Arch Int Med. 1998;158(16):1789–95.CrossRef
26.
Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict. 1991;86(9):1119–27.CrossRefPubMed
27.
Kozlowski LT, Porter CQ, Orleans CT, Pope MA, Heatherton T. Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND, and HSI. Drug Alcohol Depend. 1994;34(3):211–6.CrossRefPubMed
28.
Reynolds NR, Sun J, Nagaraja HN, Gifford AL, Wu AW, Chesney MA. Optimizing measurement of self-reported adherence with the ACTG adherence questionnaire: a cross-protocol analysis. J Acquir Immune Defic Syndr. 2007;46(4):402–9.CrossRefPubMed
29.
Lellan AT, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9(3):199–213.CrossRef
30.
McLellan AT, Luborsky L, Woody GE, O’Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis. 1980;168(1):26–33.CrossRefPubMed
31.
Brown JL, Winhusen T, DiClemente RJ, et al. The association between cigarette smoking, virologic suppression, and CD4+ lymphocyte count in HIV-infected Russian women. AIDS Care. 2017;29(9):1102–6.CrossRefPubMedPubMedCentral
32.
Gordin FM, Roediger MP, Girard PM, et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med. 2008;178(6):630–6.CrossRefPubMedPubMedCentral
33.
Lifson AR, Neuhaus J, Arribas JR, et al. Smoking-related health risks among persons with HIV in the strategies for management of antiretroviral therapy clinical trial. Am J Public Health. 2010;100(10):1896–903.CrossRefPubMedPubMedCentral
34.
Pines H, Koutsky L, Buskin S. Cigarette smoking and mortality among HIV-infected individuals in Seattle, Washington (1996-2008). AIDS Behav. 2011;15(1):243–51.CrossRefPubMed
35.
Rahmanian S, Wewers ME, Koletar S, Reynolds N, Ferketich A, Diaz P. Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc. 2011;8(3):313–9.CrossRefPubMedPubMedCentral
36.
Crothers K, Griffith TA, McGinnis KA, et al. The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J Gen Intern Med. 2005;20(12):1142–5.CrossRefPubMedPubMedCentral
37.
Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56(5):727–34.CrossRefPubMed
38.
Colado Simao AN, Victorino VJ, Morimoto HK, Reiche EM, Panis C. Redox-driven events in the human immunodeficiency virus type 1 (HIV-1) infection and their clinical implications. Curr HIV Res. 2015;13(2):143–50.CrossRefPubMed
39.
40.
Suresh DR, Annam V, Pratibha K, Prasad BV. Total antioxidant capacity—a novel early bio-chemical marker of oxidative stress in HIV infected individuals. J Biomed Sci. 2009;16:61.CrossRefPubMedPubMedCentral
41.
Sharma B. Oxidative stress in HIV patients receiving antiretroviral therapy. Curr HIV Res. 2014;12(1):13–21.CrossRefPubMed
42.
Reilly M, Delanty N, Lawson JA, FitzGerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 1996;94(1):19–25.CrossRefPubMed
43.
Pilz H, Oguogho A, Chehne F, Lupattelli G, Palumbo B, Sinzinger H. Quitting cigarette smoking results in a fast improvement of in vivo oxidation injury (determined via plasma, serum and urinary isoprostane). Thromb Res. 2000;99(3):209–21.CrossRefPubMed
44.
Chehne F, Oguogho A, Lupattelli G, Palumbo B, Sinzinger H. Effect of giving up cigarette smoking and restarting in patients with clinically manifested atherosclerosis. Prostaglandins Leukot Essent Fatty Acids. 2002;67(5):333–9.CrossRefPubMed
45.
Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med. 1995;332(18):1198–203.CrossRefPubMed
46.
Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14(4):824–35.CrossRefPubMed
47.
Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict. 2005;14(2):106–23.CrossRefPubMedPubMedCentral
48.
Winhusen T. Introduction to special issue on tobacco and other substance use disorders: links and implications. Am J Drug Alcohol Abuse. 2017;43(2):129–31.CrossRefPubMed
49.
Knudsen HK. Implementation of smoking cessation treatment in substance use disorder treatment settings: a review. Am J Drug Alcohol Abuse. 2017;43(2):215–25.CrossRefPubMed
50.
Ledgerwood DM, Yskes R. Smoking cessation for people living with HIV/AIDS: a literature review and synthesis. Nicotine Tob Res. 2016;18(12):2177–84.CrossRefPubMedPubMedCentral
Metadaten
Titel
Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection
verfasst von
Theresa Winhusen
Daniel J. Feaster
Rui Duan
Jennifer L. Brown
Eric S. Daar
Raul Mandler
Lisa R. Metsch
Publikationsdatum
13.10.2017
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 6/2018
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-017-1928-x

Weitere Artikel der Ausgabe 6/2018

AIDS and Behavior 6/2018 Zur Ausgabe

Original Paper

Fertility Intentions, Pregnancy, and Use of PrEP and ART for Safer Conception Among East African HIV Serodiscordant Couples

Original Paper

Sexual Orientation Differences in Health and Wellbeing Among Women Living with HIV in Canada: Findings from a National Cohort Study

Original Paper

Hope, the Household Environment, and Sexual Risk Behaviors Among Young Women in Rural South Africa (HPTN 068)

Original Paper

Individual, Partner, and Couple Predictors of HIV Infection among Pregnant Women in Malawi: A Case–Control Study

Original Paper

The Health and Sociocultural Correlates of AIDS Genocidal Beliefs and Medical Mistrust Among African American MSM

Original Paper

HIV-Infected Young Men Demonstrate Appropriate Risk Perceptions and Beliefs about Safer Sexual Behaviors after Human Papillomavirus Vaccination

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise